Cofoe Medical Showcases China's Hardcore Medical Device Manufacturing on CCTV
On August 18, 2023, Cofoe Medical officially debuted on CCTV channels. Centered around its core products—including oxygen concentrators, nebulizers, blood glucose meters, blood pressure monitors, and thermometers—five commercial spots will be rolled out in a multi-dimensional campaign featuring high-frequency placements across various time slots over a six-month period. These ads will air during prominent CCTV programs such as the post-Xinwen Lianbo slot on CCTV-1, CCTV-4 (Asia/Europe/America editions), and the Weather Forecast segment on CCTV News, showcasing Cofoe’s unique platform advantages and user value.
Cofoe Medical, founded in 2005, operates more than 50 subsidiaries and employs over 5,000 staff. It was listed on the Shenzhen Stock Exchange on October 25, 2021, under stock code 301087. Committed to providing users with lifelong trusted medical and health products and one-stop solutions, Cofoe Medical’s product portfolio spans five major areas: health monitoring, rehabilitation aids, respiratory support, medical nursing, and traditional Chinese medicine physiotherapy. With nearly 10,000 specifications and models, the company has grown into a leading enterprise in full-lifecycle personal health management, integrating research and development, manufacturing, sales, and services.
Cofoe Medical is committed to driving sustainable development through technological innovation, integrating independent R&D, collaborative development, and technology introduction. The company currently operates five research institutes and employs over 300 R&D professionals, forming a well-structured, multidisciplinary team spanning clinical medicine, medical laboratory science, mechanical engineering, materials science, software engineering, and computer technology. Furthermore, Cofoe Medical has established comprehensive systems for the recruitment, training, management, and incentive of R&D talent.
Cofoe Medical has continuously strengthened its R&D investment, with R&D expenses increasing by 67.8% year-on-year in 2022. Public records show that Cofoe Medical has obtained nearly 500 authorized patents, holds nearly 300 Class I medical device filing certificates and Class II medical device registration certificates, and has secured more than 80 international qualifications and certifications, including CE and FDA approvals. Cofoe Medical has successively been approved to establish a National Postdoctoral Research Station, Hunan Provincial Engineering Technology Research Center, Hunan Provincial Enterprise Technology Center, and Hunan Provincial Industrial Design Center, thereby building an integrated research platform that combines industrial research support, collaborative technological innovation, and high-end talent development.
Cofoe Medical has established production bases in Changsha, Yueyang, Nantong, and Zhuhai, boasting industry-leading manufacturing capabilities. By upgrading and retrofitting its entire production lines with automation, the company has enhanced the level of automated and informatized manufacturing. Through the implementation of refined production management and customized production of personalized products, it has gradually developed a lean management production system characterized by stable capacity, controllable costs, and superior quality, thereby achieving intelligent, large-scale production aligned with Industry 4.0 standards.
Over the past 18 years, Cofoe has cumulatively provided products and services to 50 million households, with its business covering most provinces and cities across China and exports to more than 60 countries and regions worldwide. Cofoe is one of the earliest enterprises in China to obtain licenses for internet-based B2B and B2C transactions of medical devices. Its products are available on major domestic third-party e-commerce platforms, including Tmall, JD.com, Pinduoduo, Vipshop, Suning.com, and Douyin, with transaction indices for multi-category products such as blood pressure monitors, thermometers, walking aids, nursing beds, face masks, gloves, wheelchairs, and hearing aids ranking among the industry’s leading positions. In the offline market, Cofoe has established extensive collaborations with the Top 100 pharmacy chains, with its products distributed in over 200,000 pharmacies nationwide. In 2022, Cofoe Medical achieved an operating revenue of nearly RMB 3 billion, representing a year-on-year growth of over 30%.
As the most widely distributed and influential media outlet both domestically and internationally, China Media Group (CMG) boasts powerful leadership, communication, and influence, serving as a touchstone for brands representing “Intelligent Manufacturing in China.” On August 18, 2023, Cofoe Medical partnered with CCTV to launch a comprehensive advertising campaign across multiple frequencies and time slots. Through this initiative, Cofoe will focus on one-stop solutions for chronic and common diseases, gain deeper insights into user needs, provide high-quality, reliable, and affordable products and services according to stringent standards, and broadly enhance the quality of life for the general public.
The mission of advancing health is arduous and long-term, while technological innovation knows no bounds. In the future, Cofoe Medical is committed to becoming a globally leading medical device enterprise. Upholding the responsibilities and commitments expected of China’s intelligent manufacturing sector, we will continuously strengthen our R&D and innovation capabilities, consistently enhancing the innovativeness and accessibility of Cofoe’s healthcare products and services, so that hundreds of millions of families choose and trust Cofoe.
